Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Clarus Therapeutics Holdings Inc
Revenue
Clarus Therapeutics Holdings Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
|
Revenue
$14m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45B
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$60.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
See Also
What is Clarus Therapeutics Holdings Inc's Revenue?
Revenue
14m
USD
Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Revenue amounts to 14m USD.
What is Clarus Therapeutics Holdings Inc's Revenue growth rate?
Revenue CAGR 1Y
119%
Over the last year, the Revenue growth was 119%.